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Submicroscopic copy-number imbalances contribute signiﬁcantly to the genetic etiology of human disease. Here, we report a novel mi-
croduplication hot spot at Xp11.22 identiﬁed in six unrelated families with predominantly nonsyndromic XLMR. All duplications seg-
regate with the disease, including the large families MRX17 and MRX31. The minimal, commonly duplicated region contains three
genes: RIBC1, HSD17B10, and HUWE1. RIBC1 could be excluded on the basis of its absence of expression in the brain and because it
escapes X inactivation in females. For the other genes, expression array and quantitative PCR analysis in patient cell lines compared
to controls showed a signiﬁcant upregulation of HSD17B10 and HUWE1 as well as several important genes in their molecular pathways.
Loss-of-functionmutations ofHSD17B10 have previously been associated with progressive neurological disease and XLMR. The E3 ubiq-
uitin ligase HUWE1 has been implicated in TP53-associated regulation of the neuronal cell cycle. Here, we also report segregating
sequence changes of highly conserved residues in HUWE1 in three XLMR families; these changes are possibly associated with the
phenotype. Our ﬁndings demonstrate that an increased gene dosage of HSD17B10, HUWE1, or both contribute to the etiology of
XLMR and suggest that point mutations in HUWE1 are associated with this disease too.Introduction
Mental retardation (MR) is a nonprogressive cognitive im-
pairment affecting 2%–3% of the Western population.1 So
far, point mutations and subtle deletions and insertions
have been shown to represent only a proportion (<40%)
of genetic causes underlying X-linked mental retardation
(XLMR).2,3 Microarray-comparative genomic hybridiza-
tion (array-CGH) is a powerful tool for the identiﬁcation
of submicroscopic deletions and duplications, which
would otherwise escape detection.4 Array-CGH screening
of MR patients have been reported with several different
array platforms. The majority of these studies have used
full-genome 1 Mb resolution arrays,5–7 but currently, dis-
ease-speciﬁc targeted arrays have become popular and
have been reported for the analysis of thousands of
patients with multiple congenital anomalies (MCAs)
including MR.8,9 In both cases, copy-number differences432 The American Journal of Human Genetics 82, 432–443, Februaof regions not represented on the array will be missed.
The excess of male to female patients with MR (ratio of
1.3/1) points to a genetic etiology on the X chromosome.
Although many X-linked genes have been identiﬁed in
the last decade, still in greater than 50% of XLMR families,
the genetic cause remains unidentiﬁed.3
We have screened a subset of 300 presumable X-linked
families by X chromosome-speciﬁc array-CGH and identi-
ﬁed ﬁve families with overlapping microduplications at
Xp11.22. Subsequent screening of additional patients by
qPCR identiﬁed one more positive family. The common
duplicated region contains two candidate genes, the
hydroxysteroid dehydrogenase HSD17B10 (also known as
HADH2, MHBD, or ABAD) and the E3 ubiquitin ligase
HUWE1 (also known as UREB1), both of which showed
overexpression in the affected individuals. Because a
splice-site mutation in HSD17B10 (MIM 300256) has al-
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three sequence changes of conserved residues in HUWE1
in three XLMR families, we propose that the pathways of
both genes contribute to normal cognitive development.
Subjects and Methods
Patients
As a result of a large international collaborative effort led by the
European MRX Consortium (EuroMRX), the International GOLD
Program (IGOLD), and individual collaborations, we have col-
lected DNA from a large set of well-characterized families with
XLMR. These include syndromic as well as nonsyndromic forms
of MR. For probands of all families, cytogenetic and FMR1 CGG
expansion analyses were normal. The screening protocols were
approved by the appropriate Institutional Review Board of the
University Hospitals, and informed consent was obtained from
the parents of the affected patients. Genomic DNA from patients
as well as fromhealthy controls was isolated fromperipheral blood
according to standard procedures and stored at 4C.
X Array-CGH and qPCR Analysis
Full-coverage X chromosome array-CGHwas performed essentially
as described elsewhere.11Datanormalizationwasperformedagainst
the median of the spot ratios of all clones. Cy5/Cy3 ratios for each
clone were plotted in log2 scale (y axis) relative to the position on
the X chromosome (x axis). Clones with log2 ratios outside the
0.3 to 0.3 interval were considered aberrant. Delineation of the
extent of the duplications and screening for additional duplications
was done by real-time relative quantitation (qPCR) with Sybr-green
as described previously.12 qPCR primers were designed with the
PrimerExpress software (Applied Biosystems, Foster City, CA) and
are provided upon request. All samples were run in duplicate, and
data were analyzed with the SDS software v1.2.3 of the instrument
and further analyzed in Excel with the comparative ddCt method
(Sequence Detection System, bulletin #2; Applied Biosystems).
FISH Analysis
Analysis of the position and orientation of the duplication was
performed by standard ﬂuorescent in situ hybridization (FISH) on
metaphase-chromosome spreads or interphase chromosomes of
patients and controls. DOP-PCR products of the genomic BAC
clones, RP6-29D12 (53.34 Mb) and RP1-154P24 (53.66 Mb), were
labeled with the direct labeling kit (Invitrogen, Paisley, UK) for
SpectrumOrange and SpectrumGreen (Abbott Molecular, Des
Plaines, IL), respectively as described elsewhere.7 After hybridiza-
tion according to standard protocols, signals were visualized by
digital-imaging microscopy with Cytovision capturing software
(Applied Imaging, Santa Clara, CA).
cDNA Expression Analysis by qPCR
Total RNA was extracted from white blood cells or Epstein Barr
Virus-transformed peripheral blood lymphocytes (EBV-PBLs) as
described elsewhere.12 Real-time quantitation was performed in
Leuven (Belgium) with the SYBR-green method on 50 ng cDNA
with the gene-speciﬁc primers (provided upon request) as
described elsewhere.12 The housekeeping genes ACTB and HPRT
were used for normalization. In Adelaide (Australia), expression
levels of each gene were normalized to ACTB expression in the
same sample and calculated with the relative standard curve
method. Standard curves were prepared from equally pooled con-The Amtrol cDNAs at 10-, 102-, 103-, 104-, and 105-fold dilutions for each
primer pair. Each reaction well contained 2 ml cDNA at a 10-fold
dilution, 50 pmol of each primer, and 13 SYBR green PCR Master
Mix (Applied Biosystems). Reactions were carried out with a 7300
Real-time PCR System (Applied Biosystems). Purity of the PCR
products was determined by a melt-curve analysis, and data
analysis was done with SDS Software v.1.2.2 (Applied Biosystems).
Mutations Screening
Sequence analysis of the HSD17B10 and HUWE1 genes was
performed on the 250 probands in the IGOLD project as described
elsewhere.13 This cohort includes 44 Australian families that were
analyzed here by X array-CGH including MRX17, MRX31, and
A057 but not A119. In addition, all 737 VEGA genes were checked
for mutations in MRX17, MRX31, and A057.
Exon-Expression Array
RNAwas extracted from established cell lines of two patients from
MRX17, one fromMRX31, one from A057, and ﬁve unrelated and
unaffected individuals as described above. Pooled samples of pa-
tients and controls were sent to the Australian Genome Research
Facility for labeling and hybridization onto Human Genome 1.0
ST arrays (Affymetrix, Santa Clara, CA). Background correction
and normalization was performed with robust multiarray averag-
ing (RMA) with GC correction.14 Expression values were deter-
mined for each probe set by median polish. Expression values at
the gene level were determined as the median expression across
all probe sets in the gene. Statistical signiﬁcance between affected
individuals with the duplication and unaffected controls for both
gene level and alternative splicing was determined by one-way
ANOVA. All data manipulation for exon arrays was performed
with Partek Genomics Suite V6.3beta-6.07.0613 software (Partek,
St. Louis, MI). Pathways that may be affected by the duplications
were identiﬁed with the assistance of the Database for Annotation,
Visualization and Integrated Discovery (DAVID) 2007.15
Metabolic Proﬁling
The determination of both acylcarnitines and amino acids were
performed on a Turbo V ion source (T ¼ 100C) of an Applied
Biosystems/MDS-SCIEX API4000 triple quadropole tandem mass
spectrometer (MS/MS) instrument (Concord, Ontario, Canada).
Samples were infused into the MS/MS at a ﬂow of mobile phase
(100 ml/min) with an Agilent 1100 HPLC system (Waldbronn, Ger-
many). We derivatized Whole blood-spot samples with butanolic-
HCl to form butyl-esters, the acylcarnitines were determined by
precursor scan of 85.1 amu, and the amino acids were determined
by neutral total loss of 102 amu. The levels of each acylcarnitine
and amino acid in mmol/l whole blood were determined against
the respective deuterated stable isotope with the Analyst software,
Chemoview (Applied Biosystems) and were compared against a
normal age-matched population.
Western Blotting
Proteinswere extractedby trituratingLCL in radioimmunoprecipita-
tion assay (RIPA) buffer (65.3 mM Tris [pH 7.4], 150 mM NaCl, 1%
Nonidet P40, 1 mM NaVO3, 1 mM NaF, and 13 protease-inhibitor
cocktail [Sigma, Australia]). A total of 10 mg of each extract was
separated on a 4%–12%gradient polyacrylamide gel and transferred
to nitrocellulose membrane. The membrane was blocked with 5%
skim milk and 0.1% normal goat serum and probed with a mouse
monoclonal antibody speciﬁc to human p53 at 1:1000 dilutionerican Journal of Human Genetics 82, 432–443, February 2008 433
Figure 1. Pictures of the Three Affected Individuals
of FAM3 with a Duplication at Xp11.22
Facial features of the sons (from left to right; III-3, III-
2, and III-1). Note hypertelorism, short and upslanting
palpebral fissures, epicanthi, lateral flare of eyebrows,
broad nose, simple protruding ears, open mouth, and
thick lips.(DO-7, Novacastra, UK) and a goat anti-mouse IgG conjugated to
HRP secondary antibody at 1:1000 dilution (Dako, Glostrup, Den-
mark). Bands were visualized by autoradiography after exposure to
enhanced chemiluminescent detection reagents (GE Healthcare).
An identical gel was stained with colloidal Coomassie brilliant blue
G250 so that total protein loading in each lane could be shown.
Results
Clinical Details of the Six Families with
Microduplications at Xp11.22
Family FAM3
The three sons, III-1, III-2, and III-3 (Figure 1 for pictures
and Figure 2A for pedigree) of Finnish origin present
with similar clinical ﬁndings of moderate mental retarda-
tion, unique dysmorphic faces, a remarkable speech difﬁ-
culty with hypotonic open mouth, severe dysarthria, and
only one to two word expressions, normal stature, and
OFC, short attention span, and happy disposition. The
youngest son (III-3) has a surgically repaired submucous
cleft palate. All boys have satisfactory self-help skills. The
mother (II-1) shares similar dysmorphic features with her
sons. She is successfully employed as a cleaning lady and
has normal intelligence. The sons showed normal results
on subtelomeric FISH of the X chromosome, sequencing
of MECP2, and the mutational hot spot region of XNP.
MRI brain imaging in the youngest son showed normal
structure and myelination.
Families MRX17 and MRX31
Families MRX17 and MRX31 were published earlier16,17
but were revisited; normal growth parameters and absence
of dysmorphic features were conﬁrmed. The extended ped-
igrees of both large families are shown in Figures 2B and
2C. For familyMRX31, the phenotype of themore recently
identiﬁed affected boys is also classiﬁed as mild retardation
with nondysmorphic features.
Family A057
The probands were two retarded brothers (IV-5 and IV-6 in
Figure 2D) with two affected maternal great uncles (II-7
and II-8). Both probands were born at term after normal
deliveries; IV-5 (born in 1947) had a normal birth weight
(3.7 kg), but that of IV-6 (born in 1948) was a little low
(2.7 kg) and was ascribed to poor maternal nutrition.
Both boys appeared normal except for minor hypospadias434 The American Journal of Human Genetics 82, 432–443, Februarin IV-6. Both had normal motor development, and con-
cern was only raised because of speech delay by the age
of 3 years. Both were hyperactive and were admitted to
long-term residential care at ages 8 and 11 years. As adults,
no dysmorphic facial features were recognized, and
heights (170 cm) were normal; the head circumference of
IV-5 was normal (55.5 cm), and that of IV-6 (52 cm) was
~3 SDs below the mean. Both had limited speech, needed
some help with the activities of daily living, and were
regarded as having moderate intellectual handicap. No
particular health problems were recorded until IV-5, at
the age of 55, was found to have the nephrotic syndrome
shown by renal biopsy to be due to amyloidosis, type
A-A. He died from heart failure soon after. Both maternal
uncles had been in long-term institutional care; II-7 died
in his twenties from a ‘‘clot on the brain.’’ II-8 became
demented and died of ‘‘enterocolitis’’ at age 69.
Family A119
This family consists of two affected brothers (II-1 and II-2
in Figure 2E) from a mother (I-2) who was adopted. Both
boys were slow to pass their motor milestones and speech
development. Both had febrile seizures, but II-2 continued
to have generalized seizures well controlled by valproate.
In childhood, attention-deﬁcit and hyperactivity disorders
were diagnosed in both individuals, and they were treated
with stimulants. When ﬁrst seen in adolescence, they were
off stimulant medication, and no signiﬁcant behavioral
problems were reported. They were of average stature
with a muscular build and normal head circumferences
(56 cm). There were no signiﬁcant dysmorphic features,
although the older brother had synophris and a broad
nasal root. Both were friendly and sociable. They were
regarded as having mild-to-moderate intellectual disabil-
ity. Further investigations included a CT scan on one
brother and MRI on the other, which were normal.
Family P083
The proband (III-1 in Figure 2F) suffers from mild MR with
minor additional clinical features: moderate macroorchid-
ism, synophris, and diastema between the incisor teeth
and delayed tendon reﬂexes. He was born after normal
pregnancy with birth weight (3.1 kg) and length (51 cm)
and with head circumference (34 cm) within normal
ranges. He had severe speech delay and some behavioral
problems thought to be due to lack of affection andy 2008
Figure 2. Pedigrees of Families with a Microduplication at Xp11.22
(A) FAM3, (B) MRX17, (C) MRX31, (D) A057, (E) A119, and (F) P083. Family members that could be tested for the duplication are indicated
as N (do not carry the duplication) or D (carry the duplication).stimulation. His current weight (77 kg), length (1.84 m),
and head circumference (60 cm) at the age of 19 years
are within the normal range. The results of a neurological
examination were all normal. His mother was described
as ‘‘marginal,’’ and several other male (his half-brother
and maternal nephew) and female (his half sister from
a third father) family members had normal-to-borderline
IQ or psychomotor retardation.
Clinical Features of the Three Families with Missense
Mutations in HUWE1
Family A323
This large family, with linkage to the pericentromeric
region of the X chromosome including the HUWE1 gene,
has been reported previously.18 In brief, all affected males
in the family were nondysmorphic and had macrocephaly
and moderate MR. All heterozygous females were also
macrocephalic and had signiﬁcant degrees of learning
difﬁculty. The pedigree is shown in Figure 3A.
Family UK444
The three affected males presented with moderate mental
retardation (Figure 3B). III-4 is 38 years old and lives at
home with his parents. He works in a sheltered workshop
in town and travels to work independently. He is able to
read and uses the internet extensively. He has normal
language but has occasional problems with articulation.
His growth parameters are as follows: height, 1.60 m
(0.4–2nd centile); weight, 53 kg (0.4–2nd centile); andThe Amhead circumference, 56 cm (50th centile). As a child, his
speech and language development was delayed. His motor
development was normal, although he was clumsy and
had frequent falls and poor hand-eye coordination. He
was fully toilet trained at 2 1/2 years. He had an operation
for strabismus performed at 6 years with some success. He
attended mainstream primary school but went to a special
school for children withmoderate learning disability at the
age of 11. He had little sense of danger. He is not dysmor-
phic, although he has a long face and a pointed chin. His
cousin III-1 shows similar characteristics, including the
degree of disability. He is slightly less outgoing and socia-
ble and is less conﬁdent.
Family UK106
The affected males in this family have severe to profound
mental retardation. The brothers III-6 and III-7 (Figure 3C)
are looked after at home. The boys are currently aged 17
and 12 years, respectively. Neither of the boys have any
speech nor language but communicate their basic needs
with objects of reference. The elder boy is very shy, al-
though he makes good eye contact when interacting
with familiar people. He has a ﬂexed ﬂexion deformity of
the knees but is able to walk. He needs to eat mashed or
soft food because of difﬁculties with chewing. He wears in-
continence pads day and night because he has no sense of
toileting. His height is on the ninth centile and his weight
is on the 0.4th centile, whereas his head circumference is
on the 50th centile. The younger brother is physicallyerican Journal of Human Genetics 82, 432–443, February 2008 435
Figure 3. Pedigrees of Families with a Sequence Change in HUWE1
(A) A323, (B) UK444, and (C) UK106. Additional family members that were screened are indicated on the pedigrees as WT or WT/WT (do
not carry the likely mutation), mut (carry the mutation), or WT/mut (heterozygous for the mutation). For the large family A323, the
HUWE1 gene is located within the linked interval.18 Female I.2 of family UK106 most probably is germline mosaic. Pictures of the affected
individual III-6 and III-7 of family UK106 are shown.more active at 12 years and has complete absence of eye
contact even within the family. He walks and does not
have knee contractures. He has long-standing eczema
and requires medication for constipation. The affected
uncle (II-1) lives in a residential home with one-to-one
care. He walks little because of knee contractures and pre-
fers to move around on his knees. Otherwise, he is similar
to his nephews. He has no understandable language and
has had problems with constipation. He is dry by day
and night if regularly taken to the toilet. He feeds himself
with a spoon.
X Array-CGH Screen
Upon initial screening of 200 probands (68 from XLMR
families of the EuroMRX Consortium, 124 from small
families of the Clinical Hospital of Leuven, and 8 from
Finnish origin) with idiopathic XLMR by X chromosome-
speciﬁc array-CGH, we identiﬁed a small duplication at
Xp11.22 in the Finnish family FAM3 (Figure 4A). Subse-
quently, we screened probands from 100 Australian fami-
lies. Four families from this set—MRX17, MRX31, A057
(Figures 4B–4D), and A119—were found to have duplica-
tions of the same Xp11.22 region. Affected males from
the last four families presented with mild-to-moderate
MR without additional dysmorphic features. Family FAM3436 The American Journal of Human Genetics 82, 432–443, Februapresented with a unique dysmorphic syndrome that has
not been reported up to now.
Array-CGH data revealed aberrant Cy5/Cy3 log2 ratios
for different but overlapping sets of clones indicating vary-
ing sizes of these duplications in the different families
(indicated by green arrows in Figure 5).
Mapping of the Duplications by qPCR
Subsequent qPCR analysis with 20 primer sets from the
region reﬁned the position as well as the extent of individ-
ual duplications (blue bars in Figure 5A). The duplications
varied in size from 0.4 to 0.8 Mb with a common minimal
overlapping region at 53.3–53.7 Mb as based on the
Ensembl view release 43, Feb 2007. This critical region in-
cludes four annotated genes: SMC1A, RIBC1, HSD17B10,
and HUWE1, as well as the microRNAs mir-98 and let-7f-2,
both situated within the HUWE1 gene. So far, informa-
tion on these speciﬁc microRNA subtypes is very scarce,
and a role in brain development still needs to be investi-
gated. Because SMC1A and RIBC1 escape X inactivation19
and thus are present at a double dosage in females com-
pared to males, it is unlikely that they are signiﬁcantly
involved in the observed phenotype in these families.
The larger duplications in families MRX17, A057, and
A119 also harbor the known MRX gene SMCX/JARID1C20
(MIM 314690), whereas GPR173 and TSPYL2 are thery 2008
Figure 4. X Chromosome-Specific Array-CGH Plots Obtained for Probands of Four Families Revealing the Duplications at Xp11.22
These families are (A) FAM3, (B) MRX17, (C) MRX31, and (D) A057. DNA from two unrelated MR patients were differentially labeled and
cohybridized onto the X array. The log2 normalized intensity ratios of the Cy5 (patient with duplication) and Cy3 (unrelated MR patient,
named pat A–D) signals is plotted (y axis) against the position on the X chromosome (in Mb), from Xpter to Xqter (x axis). The duplica-
tions are visible as clones with aberrant ratios >0.3 at ~53 Mb. For A057, an additional polymorphic duplication is visible as three
aberrant clones at 38 Mb. Other clones outside the normal interval (log2 ratio of 0.3 to 0.3) are polymorphic clones or outliers.additional genes duplicated in families A057 and A119.
The largest duplication in family A119 also harbors
TMEM29 and potentially SPANXN5 and some genes of
the XAGE and SSX clusters (Figure 5A). As far as we could
test, all duplications segregate with the disease in the re-The Amspective families (Figures 2A–2E). For the previously pub-
lished and mapped families (MRX17 and MRX31), the du-
plication resides within the completely overlapping
linked intervals (LOD > 2.0) of 42 Mb and 23 Mb, respec-
tively.Figure 5. Schematic Representation
of the Xp11.22 Region Showing the
Duplications
(A) Indicated from top to bottom: the loca-
tion of the qPCR primer sets (1–20), geno-
mic BAC or PAC clones, and annotated
genes present in the interval composed of
the six duplications. This region is repre-
sented for each family by the arrows indi-
cating the genomic clones from the X array
with their corresponding log2 ratios.
Clones with aberrant ratios are in green;
those with ratios in the normal interval
are open. For each family, the mapped
duplicated region, defined by qPCR, is
given as solid blue bars above these clones,
indicating that the primer sets within
these bars yielded relative copy numbers
of ~2.0 whereas the primer pairs outside
(indicated with the gray bars) gave values
~1.0. Proximal and distal breakpoints
must lie between these bars (no bars).
(B) For P083, only qPCR data are shown.
The maximal common duplicated region is
boxed (broken red line) and entirely con-
tains the genes RIBC1, HSD17B10, and
HUWE1.erican Journal of Human Genetics 82, 432–443, February 2008 437
Screening for Additional Duplications
qPCR screening with the primers designed for the
HSD17B10 gene did not reveal any duplication in 350 X
chromosomes from control samples of Finnish, Australian,
and Belgian origin. In addition, the Database for Genomic
Variants from The Center for Applied Genomics (build 36;
March 2006) and the Human Genome Structural Variation
Project (assembly May 2004) do not report this variation.
Next, we screened from the EuroMRX Consortium 50
XLMR individuals that were not yet analyzed by array-
CGH and 30 XLMR probands linked to Xp11.2, collected
by the Greenwood Genetics Center and part of the IGOLD
study, via qPCR by using HSD17B10 and HUWE1 primer
sets. One additional positive family, P083, present in the
EuroMRX panel, was identiﬁed. Fine mapping revealed
a 320 kb duplication (Figure 5B), which involved RIBC1,
HSD17B10, and HUWE1 but only part of the SMC1A
gene. The proband of P083 suffers from mild MR with
minor additional clinical features. qPCR on DNA of the
affected half-brother demonstrated that he also carries this
duplication (Figure 2F). No other family members were
available for analysis.
FISH Analysis
In order to determine the location and orientation of the
duplicated region, we performed FISH on metaphase and
interphase chromosomes from affected individuals of fam-
ilies MRX17, MRX31, and A057, for which a cell line was
available. Two differentially labeled BAC clones within
the common duplicated region revealed single ﬂuorescent
signals at Xp11 on metaphase chromosomes (Figure 6A),
demonstrating that the duplicated regions in the respec-
tive families are located very close and most probably
next to each other. A tandem arrangement was deduced
from the color order of ﬂuorescent signals on interphase
chromosomes, which was red (RP6-29D12), green (RP1-
154P24), red (RP6-29D12), and green (RP1-154P24) for all
three families (Figure 6B).
Figure 6. Representative FISH Data on
Chromosomes from Probands of Families
MRX17, MRX31, and A057
(A) Labeled DNA of RP6-29D12 (red) and
RP1-154P24 (green) were hybridized to
metaphase spreads and show signals for
both probes only at Xp11.
(B) On interphase chromosomes, alternat-
ing red-green-red-green signals are indica-
tive of a tandem duplication event.
Expression of Duplicated Genes
In silico expression analysis with Un-
igene at NCBI and immunohisto-
chemistry data from adult-mouse
brain sections (Allen Brain Atlas)
demonstrated ubiquitous expression
of HSD17B10 and HUWE1, with high
expression in the hippocampus. In contrast, the expres-
sion of RIBC1 was restricted to only a few tissues with
barely detectable levels in brain, if any. Accurate qPCR
measurement of mRNA levels of HSD17B10 and HUWE1
directly in PBLs or in EBV-transformed PBLs from controls
revealed very similar expression levels, indicating a tight
regulation of their expression in these cells. Moreover, sim-
ilar mRNA levels were detected in males and females (data
not shown), and such a ﬁnding suggests that both genes
are subject to X inactivation. Next, we determined their
relative expression in RNA extracted from blood in family
members from FAM3. A 5-fold upregulation was detected
for HSD17B10 (5.05 5 0.60) and HUWE1 (5.00 5 0.47)
in the two affected males (Figure 7), whereas no signiﬁcant
change was noticed for either gene in the carrier mother
(data not shown). Expression analysis in the ﬁve other
families was done on EBV-PBLs because of the unavailabil-
ity of fresh blood. Again, a signiﬁcant increased expression
of 2- to 5-fold was detected for HSD17B10 and HUWE1
(Figure 7). We also analyzed the relative mRNA content
of SMC1A in all six families. A substantial increase of
2- to 7-fold was detected in all families except for P083
in which no upregulation was found (Figure 7). These
data conﬁrm that SMC1A is not entirely duplicated in
P083 and, therefore, would probably not account for the
observed phenotype.
Sequencing of Genes on the X Chromosome
Sequencing of the coding exons of 737 VEGA annotated X
chromosome genes in the three families present in the
IGOLD study (MRX17, MRX31, and A057) did not reveal
any obvious disease-causing mutations, suggesting that
a simple mutation is unlikely to account for the observed
phenotypes in these families. Moreover, mutation analysis
of the genes within the duplication in all probands
from 250 XLMR families of the IGOLD project did not
detect any potential disease-associated changes in RIBC1
or HSD17B10. However, three HUWE1 missense changes438 The American Journal of Human Genetics 82, 432–443, February 2008
Figure 7. mRNA Expression Analysis of SMC1A, HSD17B10,
and HUWE1 in All Six Families with a Duplication at Xp11.22
cDNA was prepared from RNA extracted from blood (controls and
FAM3) or EBV-transformed PBL cell lines (controls, MRX17,
MRX31, A057, A119, and P083). Compared to controls, all affected
individuals showed significantly increased mRNA levels for all three
genes except for SMC1A in family P083. Expression was determined
by real-time RT-PCR with the comparative ddCt method and
normalized to the expression of HPRT and ACTB (FAM3, P083) or
with the standard curve method with ACTB for normalization
(MRX17, MRX31, A057, and A119). Expression levels are calculated
relative to the mean levels obtained in the control samples (fold
difference; y axis). Standard deviations of at least two independent
experiments are indicated for each bar.The Amproducts downstream of HSD10 in the pathways of fatty
acid (Figure S1), and valine, isoleucine, and leucine metab-
olism (data not shown). We also found alteration in the
expression of genes involved in the ubiquitin-mediated
protein-degradation pathway, consistent with the known
function of HUWE1 (data not shown). Finally, we observed
changes in the expression of many cell-cycle genes with
a central role for TP53 (P53), consistent with an upregula-
tion of HUWE1 (Figure S2).
Functional Analysis of HSD10 and HUWE1 Activities
Metabolic screening of the dehydrogenase activity of
HSD10 in lymphocytes21 will not allow for the detection
of this microduplication because we did not ﬁnd altered
levels of a number of acylcarnitines or amino acids associ-
ated with the isoleucine degradative pathway in a blood
spot of one of the patients from family MRX17, compared
to age-matched controls, by using tandem mass spectrom-
etry (MS/MS) (data not shown).
For HUWE1 activity, we analyzed the TP53 mRNA and
TP53 protein abundances by RT-qPCR and western blot-
ting, respectively, in EBV-PBLs from affected individuals
from families MRX17, MRX31, A057, P083 (duplications),
and A323 (missense change) but did not ﬁnd reduced
levels compared to control cell lines (data not shown).Discussion
were identiﬁed. One of these (12037C > T/R4013W) was
found in a large published Australian family (A323) with
XLMR and macrocephaly.18 The other two abnormalities
(8942G > A/R2981H and 12559C > T/R4187C) were iden-
tiﬁed in yet-unpublished families UK106 (severe to pro-
found MR with knee contractures) and UK444 (nonsyn-
dromic MR), respectively. All three mutated arginine
residues are highly conserved among the animal orthologs
of HUWE1 (Figure 8). None of these changes were found in
750 control individuals. Given the conservation and loca-
tion of these changes within or near known functional
domains and cosegregation with the phenotype in the
respective families (Figures 3A–3C), as well as their ab-
sence from controls, we hypothesize that these sequence
changes are deleterious to HUWE1 function.
Exon-Microarray Analysis
Exon-array analysis on pooled cDNA from MRX17,
MRX31, and A057 versus ﬁve control males showed 2- to
2.5-fold increased expression of SMC1A, HSD17B10, and
HUWE1 (Table S1 available online). In total, 1677 genes
were found to be differentially expressed, whereas 2517
genes were identiﬁed to be alternatively spliced between
the affected individuals and the controls with a p < 0.05
as deﬁned by ANOVA (Tables S1 and S2, respectively).
These genes were then analyzed against the known molec-
ular pathways of HSD10 and HUWE1 with the molecular-
interaction databases DAVID and KEGG. We noticed for
example a downregulation of ACAA1 that metabolizesX chromosome-speciﬁc array-CGH analysis of XLMR fam-
ilies has uncovered several disease-associated as well as
polymorphic submicroscopic copy-number changes.11,22
However, for several of these aberrations, the association
with the disease is not clear. In our screen of 300 presumed
XLMR families, we identiﬁed six different but overlapping
microduplications at Xp11.22. The proposed causal role
for this duplication comes from the fact that all segregate
with the disease in the six families, and it was never found
in controls (own screen and online databases). The com-
mon 0.32 Mb region contains four genes: part of SMC1A,
RIBC1, HSD17B10, and HUWE1. The RIB43A domain
with coiled coils 1 (RIBC1) gene of unknown function
does not seem to be expressed in the brain. The fact that
SMC1A is not completely duplicated in P083, as reﬂected
in its normal relative expression proﬁle in a cell line
derived from this patient, strongly suggests that SMC1A
duplication is unlikely to contribute to the phenotype
seen in these families. Mutations in SMC1A have recently
been associated with Cornelia de Lange syndrome (MIM
300590).23 This leaves two candidate genes for which
a 2-fold increase in expression might be responsible for
the cognitive deﬁcit.
The gene 17 b-hydroxysteroid dehydrogenase type 10
(HSD17B10) codes for a 261 amino acid mitochondrial en-
zyme HSD10 important in isoleucine and branched-chain
fatty-acid degradation (reviewed in 24). Interestingly, three
missense mutations in this gene have been associatederican Journal of Human Genetics 82, 432–443, February 2008 439
Figure 8. Missense Changes in the HUWE1 Gene Identified in Three XLMR Families
Partial ClustalW alignments of HUWE1 orthologs in the regions surrounding (A) R2981H (UK106), (B) R4013W (A323), and (C) R4187C
(UK444) amino acid changes. Whereas the R2981 is invariable across all orthologs, R4013 and R4187 are highly conserved. In (D), the
position of these arginine residues within the HUWE1 protein is indicated with the arrows. The cartoon above the conservation plot
(Scorecons) indicates domains within the HUWE1 protein. Pfam 06012 (aa 104–374) and Pfam 06025 (aa 424–704 and 762–815) domains
are of unknown function, WWE domain (aa 1617–1678) might be involved in the regulation of ubiquitin-mediated proteolysis, and HECT
domain (aa 4036–4374) is the catalytic domain of HUWE1 ubiquitin protein ligase.with progressive neurodegenerative disease,25 whereas a
silent mutation, which affects alternative splicing of exon
5, has recently been related to a syndromic form of MR
with choreoathetosis.10 Additionally, a role in Alzheimer’s
as well as Parkinson’s disease has been suggested through
binding with amyloid-b peptide and regulation of dopa-
mine-containing neurons, respectively.26,27 Elevated HSD10
levels were found in hippocampi of Alzheimer’s patients.28
It is therefore likely that not only a reduced activity but
also an increased dosage of HSD10 might interfere with
normal cognition through disturbed metabolism of neuro-
steroid modulators of GABAA receptors.
28 The localization
of the HSD10 protein to postsynaptic protein complexes29
further reinforces its likely role in neuronal communica-
tion. It is of interest that in family A057, one affected
brother died of amyloidosis at the age of 55.
The large HECT, UBA, and WWE domain-containing
protein 1 (HUWE1) is an E3 ubiquitin ligase initially found
implicated in oncogenesis. In colorectal cancers, overex-
pression of HUWE1 leads to increased ubiquitination
of the tumor suppressor TP53 with its subsequent degrada-
tion.30 Because a critical role for TP53 has been implicated
inmaintaining the balance between the continuous gener-440 The American Journal of Human Genetics 82, 432–443, Februaration of neuroblasts and their elimination through apo-
ptosis,31 reduced levels of TP53 are expected to result in
developmental abnormalities in the nervous system. This
process has been demonstrated in Tp53-deﬁcient mice in
part because of overproduction of neuronal precursors.32
Moreover, ubiquitin and protein degradation have been
implicated in neuronal function (reviewed in33), and
mutations in several proteins involved in the ubiquitin
pathway have been related to MR.13,34–37 Finally, dysfunc-
tion of the ubiquitin metabolism is a hallmark in several
neurological diseases.38,39
Taken together, our data demonstrate that duplications
varying in size from 0.3–0.8 Mb at Xp11.22, which include
HSD17B10 and HUWE1, contribute to disturbance of nor-
mal cognitive development. The phenotype of our patients
with this duplication is nonsyndromic with mild-to-mod-
eratemental handicap in ﬁve out of six families, suggesting
that this is the group in whom screening is advisable.
We do not have as yet an explanation for the syndromic
phenotype observed in family FAM3 who carries a rather
small duplication. The signiﬁcant higher relative expres-
sion of HUWE1 in this family compared to the others
with this duplication (Figure 7) might have affected thisy 2008
peculiar phenotype. Also, the relative high expression
levels (4- to 7-fold) observed for SMC1A and HSD17B10
in families with a 2-fold increase in copy number of these
genes remains elusive. Whereas there is one mutation of
HSD17B10 described in XLMR associated with choreoatho-
tosis,10 theHUWE1 gene had not been implicated in XLMR
so far. Our data indicate that HUWE1 point mutations
indeed are associated with MR. On the basis of global-
expression analysis, which revealed altered mRNA levels
for several genes involved in the cell-cycle pathway, we
propose that HUWE1 might be the major but unlikely
the only contributor to the observed phenotype in those
with a duplication. Ultimately, identiﬁcation of a duplica-
tion carrying either one or the other of the candidate genes
or of an appropriate animal model will be required to distill
the causal gene in this new microduplication hot spot.
These ﬁndings will provide additional insight into its role
in normal brain development.
Other examples of genes for which duplications, mis-
sense mutations, and deletions herein result in cognitive
phenotypes are PLP1 (MIM 300401), resulting in Peli-
zaeus-Merzbacher disease, PMP22 (MIM 601097) in Char-
cot-Marie-Tooth disease, APP (MIM 104760) in Alzheimer
disease, and MECP2 (MIM 300005) in severe forms of syn-
dromic MR.12,40–42 HSD17B10, HUWE1, or both seem to
join this growing list, and it is expected that several more
will follow.
Supplemental Data
Two ﬁgures and two tables are available at http://www.ajhg.org/.
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